Global Alliance for TB Drug Development (TB Alliance), a not-for-profit product development partnership (PDP) accelerating the discovery and development of new drugs to fight tuberculosis (TB), has appointed Robert C. Lorette, Esq., Senior Vice President of Business Development.
“I am eager to use my skills and experience in the field of corporate development to contribute to advancing such a worthy, life-saving cause,” said Mr. Lorette. “Over the past decade, the TB Alliance has made great strides in the pursuit of new and improved treatments for TB, giving hope to millions of patients around the world. I plan to help ensure that the organization’s upcoming years are even more productive and historic.”
In this role, Mr. Lorette will help lead the TB Alliance’s efforts to establish agreements and strategic alliances within the context of the PDP business model, and thus play an integral role in achieving the portfolio development and related resource mobilization goals of the TB Alliance.
“We are excited to welcome Bob to the TB Alliance team and are confident that his extensive experience and track record in building alliances will play a crucial role in continuing the TB Alliance’s momentum in terms of partnering, portfolio development, and organizational growth,” said Dr. Mel Spigelman, President and Chief Executive Officer, TB Alliance.
Before joining the TB Alliance, Mr. Lorette founded and was President and Chief Executive Officer of Boston Life Science Advisors, a corporate development consulting firm dedicated to serving biotech, medical device and other life science organizations. He also co-founded and served as Managing Director of Transform Ventures LLC, a firm that brings capital, executive leadership, and engineering and manufacturing resources together to rapidly advance medical device technologies to a significant value inflection point.
Before founding these two companies, Mr. Lorette served as Chief Business Officer and Senior Vice President of Dynogen Pharmaceuticals, Inc., a clinical-stage drug development company focusing on gastrointestinal and genitourinary disorders. Earlier in his career, Mr. Lorette served in various management, corporate development, and legal roles for organizations such as Boston Healthcare Associates, Inc., UroMed Corporation, and Bausch & Lomb Incorporated.
Mr. Lorette received his law degree from Syracuse University College of Law and is admitted to practice law in Massachusetts, Connecticut, and New York. Additional accreditations include a master’s degree in public administration from the Maxwell School of Syracuse University and a bachelor’s degree in economics from the College of the Holy Cross. Mr. Lorette also attended the Program for Management Development at the Harvard Business School.
About the Global Alliance for TB Drug Development
The TB Alliance is a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection.
Working with public and private partners worldwide, the TB Alliance is leading the development of the most comprehensive portfolio of TB drug candidates in history. It is committed to ensuring that approved new regimens are affordable, adopted and available to those who need them.
The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid, the Netherlands Ministry of Foreign Affairs (DGIS), the United Kingdom Department for International Development (DFID), and the United States Agency for International Development (USAID). For more information on TB drug development and the TB Alliance, please visit www.tballiance.org.
Contact:
Joanna Breitstein
TB Alliance
joanna.breitsein@tballiance.org
Phone: +646-616-8613
Mobile: +917-361-6683